These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 2737759)

  • 1. Association experiments with aerobic and anaerobic pathogens: a model of in-vitro susceptibility testing in mixed infections. Activity of enoxacin, clindamycin, and metronidazole.
    Heizmann WR; Schmid R; Heilmann F; Werner H
    Infection; 1989; 17(3):160-4. PubMed ID: 2737759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections.
    Heizmann WR; Heilmann F; Egeler B; Werner H
    Infection; 1990; 18(2):117-21. PubMed ID: 2332245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Susceptibility of clinically important Bacteroides species against enoxacin-metronidazole and enoxacin-clindamycin combinations].
    Heizmann WR; Werner H; Schmid R
    Infection; 1989; 17 Suppl 1():S11-3. PubMed ID: 2807557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.
    Pefanis A; Thauvin-Eliopoulos C; Holden J; Eliopoulos GM; Ferraro MJ; Moellering RC
    Antimicrob Agents Chemother; 1994 Feb; 38(2):252-5. PubMed ID: 8192453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibility of anaerobic and aerobic bacteria isolated from patients with mixed infections in Nicaragua.
    Cáceres M; Carrera E; Palma A; Berrios G; Weintraub A; Nord CE
    Rev Esp Quimioter; 1999 Dec; 12(4):332-9. PubMed ID: 10855012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rate of non-susceptibility to metronidazole and clindamycin in anaerobic isolates: Data from a clinical laboratory from Karachi, Pakistan.
    Sheikh SO; Jabeen K; Qaiser S; Ahsan ST; Khan E; Zafar A
    Anaerobe; 2015 Jun; 33():132-6. PubMed ID: 25800668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
    Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
    J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergic activity, for anaerobes, of trovafloxacin with clindamycin or metronidazole: chequerboard and time-kill methods.
    Ednie LM; Credito KL; Khantipong M; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2000 May; 45(5):633-8. PubMed ID: 10797085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin in combination with metronidazole.
    Werk R; Schneider L
    Infection; 1988; 16(4):257-60. PubMed ID: 3182096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sensitivity of strict anaerobic bacteria to metronidazole, cefoxitin, and clindamycin].
    Dubreuil L; Derriennic M; Reynaud A; Devos J; Romond C; Courtieu A
    Pathol Biol (Paris); 1985 Nov; 33(9):899-903. PubMed ID: 3909082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria.
    Kowalsky SF; Echols RM; McCormick EM
    J Antimicrob Chemother; 1990 May; 25(5):767-75. PubMed ID: 2373663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Common pathogens of surgical infections and their drug sensitivities].
    Zhang YP
    Zhonghua Wai Ke Za Zhi; 1989 Apr; 27(4):215-6, 253. PubMed ID: 2805989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification of anaerobic bacteria isolated from various clinical specimens and determination of antibiotic susceptibilities].
    Doğan M; Baysal B
    Mikrobiyol Bul; 2010 Apr; 44(2):211-9. PubMed ID: 20549955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of cefoperazone, cefoperazone plus sulbactam, ciprofloxacin, clindamycin, metronidazole, and penicillin G against anaerobic bacteria in an animal model.
    Moody JA; Fasching CE; Sinn LM; Gerding DN; Peterson LR
    J Lab Clin Med; 1990 Feb; 115(2):190-5. PubMed ID: 1967626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole.
    Boeckh M; Lode H; Deppermann KM; Grineisen S; Shokry F; Held R; Wernicke K; Koeppe P; Wagner J; Krasemann C
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2407-14. PubMed ID: 2088195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting antibiotic tolerance in anaerobic biofilms associated with oral diseases: Human antimicrobial peptides LL-37 and lactoferricin enhance the antibiotic efficacy of amoxicillin, clindamycin and metronidazole.
    Wuersching SN; Huth KC; Hickel R; Kollmuss M
    Anaerobe; 2021 Oct; 71():102439. PubMed ID: 34454095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between penicillin, clindamycin or metronidazole and gentamicin against species of clostridia and anaerobic and facultatively anaerobic gram-positive cocci.
    Brook I; Walker RI
    J Antimicrob Chemother; 1985 Jan; 15(1):31-7. PubMed ID: 3972757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The growth-inhibitory properties of meropenem against anaerobes of clinical importance.
    Watt B; Naden M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():119-24. PubMed ID: 2808203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.